Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $54.2 million.

  • Editas Medicine's Non-Current Deffered Revenue changed 0.0% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $54.2 million for FY2024, which is 1065.32% down from last year.
  • Per Editas Medicine's latest filing, its Non-Current Deffered Revenue stood at $54.2 million for Q3 2025, which was down 0.0% from $54.2 million recorded in Q2 2025.
  • Editas Medicine's 5-year Non-Current Deffered Revenue high stood at $68.9 million for Q2 2022, and its period low was $54.2 million during Q1 2024.
  • Its 5-year average for Non-Current Deffered Revenue is $58.5 million, with a median of $60.7 million in 2022.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 6010.22% in 2021, then soared by 2474.96% in 2022.
  • Editas Medicine's Non-Current Deffered Revenue (Quarter) stood at $60.9 million in 2021, then fell by 0.36% to $60.7 million in 2022, then changed by 0.0% to $60.7 million in 2023, then decreased by 10.65% to $54.2 million in 2024, then changed by 0.0% to $54.2 million in 2025.
  • Its Non-Current Deffered Revenue was $54.2 million in Q3 2025, compared to $54.2 million in Q2 2025 and $54.2 million in Q1 2025.